Navigation Links
Dendreon Presents Preclinical Data Demonstrating Activity of Trp-p8 agonist, D-3263, in Benign Prostatic Hyperplasia
Date:5/21/2008

Active cellular immunotherapy holds promise because it may provide patients with a meaningful clinical benefit, such as survival, combined with low toxicity. The Company has its headquarters in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com.

Except for historical information contained herein, this news release contains forward-looking statements that are subject to, risks and uncertainties surrounding the presentation of data to the FDA and approval of product applications by the FDA and risks and uncertainties inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics. Factors that may cause such differences include risks related to our limited operating history, risks associated with completing our clinical trials, the risk that the safety and/or efficacy results of existing clinical trials or from additional clinical trials will not support approval, the risk that the FDA may interpret data differently than we do or require more data or a more rigorous analysis of data than expected, the risk that the FDA will not approve a product for which a biologics license has been applied, the risk that the results of a clinical trial may not be indicative of results obtained in a later clinical trial, risks that we may lack the financial resources and access to capital to fund required clinical trials or commercialization of products, our dependence on the efforts of third parties, and our dependence on intellectual property. Further information on the factors and risks that could affect Dendreon's business, financial condition and results of operations are contained in Dendreon's public disclosure filings with the U.S. Securities and Exchange Commission, which are available at

SOURCE Dendreon Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Presents Data Correlating the Cumulative Potency of PROVENGE(R) to Overall Survival
2. Dendreon Completes Target Enrollment of 500 Patients in Phase 3 IMPACT Study of Provenge(R) For Advanced Prostate Cancer
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis
5. Indevus Presents Successful Phase III NEBIDO(R) Data at American Urological Association
6. Neurobiological Technologies, Inc. Presents Dosing Rationale for Viprinex(TM) (ancrod) at the European Stroke Conference
7. Napo Presents at ISPOR Meeting in Toronto
8. Alpharma Presents Data Addressing Abuse Liability Features, Safety and Efficacy on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) at the American Pain Society Annual Scientific Session
9. Dr. Calvin Grant Presents Results from Xibrom(TM) Combination Therapy with Lucentis(R) at the 2008 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO)
10. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
11. Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver (EASL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... -- Quietly, sedately, Morocco,s pharmaceutical sector is ... industry is strong, with a well-developed base of local ... One place where the quality of Moroccan ... has quietly become the second largest African exporter of ... Indeed, Moroccan pharma companies have been making inroads as ...
(Date:7/31/2015)... SAN DIEGO , July 31, 2015 ... Eisai Co., Ltd. (Headquarters: Tokyo , ... Halozyme Therapeutics, Inc. (Headquarters: San Diego, California ... , "NASDAQ: HALO") have signed a clinical collaboration agreement ... , "eribulin") in combination with Halozyme,s investigational drug PEGPH20 ...
(Date:7/31/2015)... India , July 31, 2015 ... CRM solutions for video, data and cloud computing ... with a leading pharma giant for Internet of ... different IoT applications offered on subscription model. ... Pharma giant is striving for business innovations ...
Breaking Medicine Technology:PharmaBoardroom Releases New Morocco Pharmaceuticals Report 2PharmaBoardroom Releases New Morocco Pharmaceuticals Report 3Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 2Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 3Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 4Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 5Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 6Magnaquest Signs a POC With a Leading Pharma Giant in Europe to Manage Subscription Management and Billing for Internet of Things (IoT) 2
... that a new market research report is available in ... Sales Forces , http://www.reportlinker.com/p0154035/Reportlinker-Adds-Reinventing-Pharmaceutical-Sales-Forces.html ... groups and leaner economic times have forced a new ... the previous decade is dead. Faced with the challenge ...
... Oct. 8 Ethicon Endo-Surgery today announced the company ... for the research and design process used in the ... company was recognized among thousands of entries for its ... collaboration with surgeons across the globe to identify specific ...
Cached Medicine Technology:Reportlinker Adds Reinventing Pharmaceutical Sales Forces 2Reportlinker Adds Reinventing Pharmaceutical Sales Forces 3Reportlinker Adds Reinventing Pharmaceutical Sales Forces 4Reportlinker Adds Reinventing Pharmaceutical Sales Forces 5Reportlinker Adds Reinventing Pharmaceutical Sales Forces 6Reportlinker Adds Reinventing Pharmaceutical Sales Forces 7Ethicon Endo-Surgery Wins Prestigious International Design Award for Innovative Development of HARMONIC FOCUS(TM) 2Ethicon Endo-Surgery Wins Prestigious International Design Award for Innovative Development of HARMONIC FOCUS(TM) 3
(Date:8/1/2015)... ... August 01, 2015 , ... The condition where veins are enlarged and ... often causing pain and discomfort. Those who spend a lot of time on their ... Vein Center is doing what it can to create awareness and provide a cure ...
(Date:8/1/2015)... ... 2015 , ... Tina Wilcoxson, owner of Freeport Maine’s Royal River Natural Foods, ... the National Retail Federation, the largest retail trade association in the world, for her ... owners to be named as such. According to the NRF’s website, Retail Champions are ...
(Date:8/1/2015)... ... August 01, 2015 , ... ... (“GPP”) portfolio company has acquired Premier Physical Therapy & Wellness (“Premier”) — with ... of state-of-the-art clinics. , “Our acquisition of Premier Physical Therapy & Wellness solidifies ...
(Date:8/1/2015)... ... August 01, 2015 , ... Lume Wellness creators Alex, Robert, and Sam ... on the Apple AppStore. , The app is designed to track various metrics ... a tool to view personal health and use this information for positive behavior modification. ...
(Date:8/1/2015)... ... 01, 2015 , ... “ reTXT ” was featured on NewsWatch as part ... on the market for iOS, Android, and Windows. Joe Toohey, the host of AppWatch ... clarify, edit and delete any message including ones already sent. , While text messaging ...
Breaking Medicine News(10 mins):Health News:Northeast Houston Vein Center Warns Men about Varicose Veins 2Health News:Northeast Houston Vein Center Warns Men about Varicose Veins 3Health News:Local Retail Advocate Wins National Recognition 2Health News:Professional Physical Therapy Now Largest Outpatient Physical Therapy Provider in Northeast With Acquisition of Premier Physical Therapy & Wellness 2Health News:Lume Wellness Launches Health and Fitness Tracker iPhone App 2Health News:Correct Auto-Correct and Clarify the Unclear with reTXT Messaging App 2
... that stimulates digestive nerves, U.K. study suggests , , MONDAY, ... recovery of intestinal function after all or part of ... researchers who reviewed data from five clinical trials involving ... pass contents after surgery (postoperative ileus) is normal among ...
... ... Patient, BEIJING, Aug. 18 ... and innovator of the high jump technique,dubbed the "Fosbury Flop," which revolutionized ... in March. After,undergoing surgery, radiation and chemotherapy treatment at the University,of New ...
... could be key, researchers say , , MONDAY, Aug. 18 (HealthDay ... up with an unruly head of hair from time to ... find out why it misbehaves -- and how to tame ... first of its kind, German researchers say they,ve gotten extreme-close-up ...
... PHILADELPHIA, Aug. 18 Independence Blue Cross (IBC),today ... the American Diabetes,Association,s (ADA,s) Step Out: Walk to ... October 4, 2008., The new family- and ... efforts to stem the growing diabetes epidemic by ...
... Aug. 18 For years, Labor Day has meant,picnics, ... millions,of working people, it also could rekindle memories of ... have to worry about health insurance. Times,are changing and ... health insurance coverage,especially in small businesses. The National Coalition ...
... whose families experience a high degree of interpersonal conflict ... compared with Asian Americans overall, according to a new ... is tripled even among those who have never had ... be reported during a 2 p.m. (EDT) poster session, ...
Cached Medicine News:Health News:Gum Chewing May Speed Colon Surgery Recovery 2Health News:Olympic Gold Medalist Inspires Cancer Patients Through Blog 2Health News:Science May Banish Bad Hair Days 2Health News:Independence Blue Cross Signs on as Presenting Sponsor of American Diabetes Association's Step Out: Walk to Fight Diabetes in Philadelphia 2Health News:Independence Blue Cross Signs on as Presenting Sponsor of American Diabetes Association's Step Out: Walk to Fight Diabetes in Philadelphia 3Health News:Independence Blue Cross Signs on as Presenting Sponsor of American Diabetes Association's Step Out: Walk to Fight Diabetes in Philadelphia 4Health News:Laboring Without Health Insurance? HSAs May Be an Affordable Option 2Health News:Suicide in Asian Americans 2
Amylase (EPS-G7, kinetics), Wavelength: 405 nm. Linear range; 5-1500 IU/L....
g-GT Liquid Reagent (Kinetic Method). Wavelength: 405 nm. Linear range: 0-200 U/mL. Prepare Working Reagent in the ratio of 5 parts R1 to 1 part of R2, (i.e., 50 mL R1 and 10 mL R2)....
Intended for the quantitative determination of calcium in serum. Endpoint Reaction. Reaction complete within one minute, color developed is stable for 30 minutes. Wavelength: 570 nm. Linearity: 16 mg...
... for the quantitative determination of ... or plasma. Two vials, dry ... must be purchased separately for ... reaction. Wavelength: 340 nm. Linearity: ...
Medicine Products: